ResearcherUniversity of AlabamaNo recent work listed

Tha Luong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6686-5531; OpenAlex author ID A5014146021. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Co-author DOI 10.1016/j.semcancer.2022.12.004 ↗
Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Co-author DOI 10.1016/j.cytogfr.2022.09.001 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ganji Purnachandra Nagaraju · 2 shared papers, 2022–2023 · strength 0.49
- Paper Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistanc… DOI 10.1016/j.semcancer.2022.12.004 ↗
- Paper Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. DOI 10.1016/j.cytogfr.2022.09.001 ↗
Bassel F. El‐Rayes · 2 shared papers, 2022–2023 · strength 0.49
- Paper Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistanc… DOI 10.1016/j.semcancer.2022.12.004 ↗
- Paper Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. DOI 10.1016/j.cytogfr.2022.09.001 ↗
Batoul Farran · 1 shared paper, 2023 · strength 0.26
- Paper Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistanc… DOI 10.1016/j.semcancer.2022.12.004 ↗
Yuvasri Golivi · 1 shared paper, 2022 · strength 0.22
- Paper Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. DOI 10.1016/j.cytogfr.2022.09.001 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.